Key Takeaways and Closing Thoughts on ADCs

First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.

Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.

Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.

AI-assisted scoping review of code sharing in clinical prediction model research

Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.

The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.

Roswell Park Comprehensive Cancer Center has earned national recognition in 2026 from the American Medical Association as a Joy in Medicine organization.